Cover Image
市場調查報告書

人類巨細胞病毒包膜糖蛋白B (gB):開發中產品分析

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 371948
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
人類巨細胞病毒包膜糖蛋白B (gB):開發中產品分析 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 47 Pages
簡介

本報告提供以人類巨細胞病毒包膜糖蛋白B (gB)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

人類巨細胞病毒包膜糖蛋白B (gB) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Astellas Pharma Inc.
  • Trellis Bioscience, Inc.
  • Vakzine Projekt Management GmbH
  • VBI Vaccine Inc
  • Vical Incorporated

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0500TDB

Summary

Global Markets Direct's, 'Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016', provides in depth analysis on Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted pipeline therapeutics.

The report provides comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) Overview
  • Therapeutics Development
    • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Stage of Development
    • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Therapy Area
    • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Indication
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Companies
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Trellis Bioscience, Inc.
    • Vakzine Projekt Management GmbH
    • VBI Vaccines Inc
    • Vical Incorporated
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
    • ASP-0113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CyMVectin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRL-345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBI-1501A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBI-1901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPM-2001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Projects
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Featured News & Press Releases
    • Aug 22, 2016: VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review
    • Jun 23, 2016: VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate
    • Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
    • Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington
    • Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference
    • Nov 20, 2015: VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology
    • Nov 06, 2015: VBI Vaccines to Present Update and New Data Supporting its CMV Vaccine Program at the World Vaccine Congress Europe
    • Aug 26, 2015: VBI Vaccines to Provide an Update on its CMV Vaccine Program at the Tenth Annual IMVACS Summit
    • May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients
    • Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference
    • Apr 09, 2015: VBI Vaccines Announces New Data Supporting the Manufacture of Its Prophylactic CMV Vaccine Candidate
    • Nov 24, 2014: VBI To Present At The LD Micro Conference
    • Sep 15, 2014: New Data Supporting VBI's Prophylactic Cytomegalovirus (CMV) Vaccine Candidate (VBI-1501A) Presented at the 54th ICAAC Conference in Washington, D.C.
    • Mar 27, 2014: VBI Begins GMP Tech Transfer to Paragon Bioservices
    • Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Astellas Pharma Inc., H2 2016
  • Pipeline by Trellis Bioscience, Inc., H2 2016
  • Pipeline by Vakzine Projekt Management GmbH, H2 2016
  • Pipeline by VBI Vaccines Inc, H2 2016
  • Pipeline by Vical Incorporated, H2 2016
  • Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top